Antibody News and Research RSS Feed - Antibody News and Research

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.
Five-year $10.7M grant to study control, prevention of sexually-transmitted infections

Five-year $10.7M grant to study control, prevention of sexually-transmitted infections

The University of Maryland Schools of Dentistry (UM SOD) and Medicine (UM SOM) jointly announced today that they have received a five-year $10.7 million grant award from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health to study the causes, prevention and treatment of sexually-transmitted diseases (STDs). [More]
EMD Serono begins MSB0010718C Phase II study in mMCC patients

EMD Serono begins MSB0010718C Phase II study in mMCC patients

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the initiation of an international Phase II study designed to assess the efficacy and safety of MSB0010718C, an investigational fully human IgG1 monoclonal antibody that binds to programmed death-ligand 1 (PD-L1). [More]
MedMira adds three new rapid vertical flow tests to Multiplo product line

MedMira adds three new rapid vertical flow tests to Multiplo product line

MedMira, Inc. is expanding its Multiplo product line with the addition of three new multiplex tests that deliver instant, simultaneous, single-cartridge results for syphilis (TP), HIV, and hepatitis C. [More]
EMA recommends full marketing approval for IMBRUVICA in the European Union

EMA recommends full marketing approval for IMBRUVICA in the European Union

Pharmacyclics, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending the granting of full marketing approval for IMBRUVICA (ibrutinib) in the European Union. [More]
Immunologic mechanism makes broadly neutralizing antibodies in people infected with HIV

Immunologic mechanism makes broadly neutralizing antibodies in people infected with HIV

Scientists at Duke Medicine have found an immunologic mechanism that makes broadly neutralizing antibodies in people who are HIV-1 infected. [More]
Lyfebulb, Immune collaborate to increase awareness of bullous pemphigoid

Lyfebulb, Immune collaborate to increase awareness of bullous pemphigoid

Lyfebulb, the International Pemphigus Pemphigoid Foundation (IPPF) and Immune Pharmaceuticals Inc., announced a collaboration to increase awareness of unmet needs in treating bullous pemphigoid last night at an event attended by more than sixty patients, physicians, scientists and other interested parties. [More]
George Mason University researchers use dyes to paint new picture of diseases

George Mason University researchers use dyes to paint new picture of diseases

By using brightly hued dyes, George Mason University researchers discovered an innovative way to reveal where proteins touch each other, possibly leading to new treatments for cancer, arthritis, heart disease and even lung disease. [More]
Scientist develops highly accurate device for diagnosing fatal lung disease

Scientist develops highly accurate device for diagnosing fatal lung disease

A scientist from the University of Exeter has developed a simple, cheap and highly accurate device for diagnosing a frequently fatal lung disease which attacks immune deficient individuals such as cancer patients and bone marrow transplant recipients. [More]
Shire, ArmaGen partner to develop AGT-182 drug for treatment of Hunter syndrome

Shire, ArmaGen partner to develop AGT-182 drug for treatment of Hunter syndrome

Shire plc, the global specialty biopharmaceutical company, and ArmaGen, a US privately held biotechnology company, today announced a worldwide licensing and collaboration agreement for AGT-182, an investigational enzyme replacement therapy (ERT) for the potential treatment of both the central nervous system (CNS) and somatic manifestations in patients with Hunter syndrome (MPS II). [More]
Immunosignaturing holds promise for accurate diagnosis of Valley Fever

Immunosignaturing holds promise for accurate diagnosis of Valley Fever

On July 5, 2011, a massive wall of dust, ("haboob," in Arabic), blanketed Phoenix, Arizona, creating an awesome spectacle, (or stubborn nuisance, depending on your perspective). Dust storms are a common occurrence in the arid desert environments of the American Southwest. [More]
Marker identified for population of renal cancer cells with stem-cell-like features

Marker identified for population of renal cancer cells with stem-cell-like features

Researchers have identified a population of clear cell renal cell carcinoma cells positive for the CTR2 marker that possess some stem-cell-like features and are able to induce an angiogenic response in vivo. [More]
Marker identified for population of renal cancer cells with stem-cell-like features

Marker identified for population of renal cancer cells with stem-cell-like features

Researchers have identified a population of clear cell renal cell carcinoma cells positive for the CTR2 marker that possess some stem-cell-like features and are able to induce an angiogenic response in vivo. Targeting CTR2 was shown to decrease drug resistance to cisplatin. [More]
Researchers collaborate to tackle rare diseases

Researchers collaborate to tackle rare diseases

Support from a network of leading researchers across Europe specialised in a rare auto-immune disease with unmet medical needs could help test several novel treatments [More]
Chemclin's HIV kits for in-vitro qualitative determination of Anti-HIV 1+2

Chemclin's HIV kits for in-vitro qualitative determination of Anti-HIV 1+2

Chemclin's HIV kits are available for in-vitro qualitative determination of Antibody to Human Immunodeficiency Virus Type 1 and Type 2 (Anti-HIV 1+2) and P24 antigen of HIV in human serum or plasma by a sandwich chemiluminescent assay method. [More]
Chemclin's Anti-TP assay provides components for in-vitro qualitative determination of Anti-TP

Chemclin's Anti-TP assay provides components for in-vitro qualitative determination of Anti-TP

Chemclin's Anti-TP assay provides components for in-vitro qualitative determination of Antibody to Treponema Pallidum (Anti-TP) in human serum or plasma by a double - antigen sandwich chemiluminescent assay method. [More]
Peer-led interventions can reduce depression and anxiety in mothers of kids with autism

Peer-led interventions can reduce depression and anxiety in mothers of kids with autism

Peer-led interventions that target parental well-being can significantly reduce stress, depression and anxiety in mothers of children with disabilities, according to new findings released today in the journal Pediatrics. [More]

Chemclin's Anti-TB assay helps in qualitative determination of Anti-TB in human serum

Chemclin's Anti-TB assay provides components for in-vitro qualitative determination of Antibody to Mycobacterium Tuberculosis (Anti-TB) in human serum or plasma by an indirect chemiluminescent assay method. [More]
New chromatin immunoprecipitation sequencing kit developed by Porvair Sciences

New chromatin immunoprecipitation sequencing kit developed by Porvair Sciences

Porvair Sciences has developed a new ChIP sequencing assay kit extending the benefits of their proprietary Chromatrap® solid state ChIP technology to preparation of purified Chromatin for the generation of sequencing libraries. [More]
Randox's Acusera Immunoassay Speciality 1 quality control receives FDA clearance

Randox's Acusera Immunoassay Speciality 1 quality control receives FDA clearance

In Q3 of 2013, Randox announced that the Food and Drug Administration has approved the company's Acusera Immunoassay Speciality 1 quality control for use in US laboratories. [More]
New molecular analysis tool to detect targets for immunotherapy in early-stage breast cancers

New molecular analysis tool to detect targets for immunotherapy in early-stage breast cancers

Yale Cancer Center researchers used a new molecular analysis tool to accurately detect the level of an important target for immunotherapy in early-stage breast cancers. [More]